While Alzheimer's disease is the most common type of dementia, there's another variation that is also relatively prevalent.

CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a ...

CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...

Strapped with an extra APP, people with Down’s syndrome are all but destined to develop Alzheimer’s dementia if they live ...

AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial ...